Published in Drug Discov Today on January 01, 2006
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol (2010) 1.66
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J (2009) 1.48
Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem (2012) 1.46
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A (2008) 1.34
Engineering the variable region of therapeutic IgG antibodies. MAbs (2011) 1.33
Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J (2012) 1.20
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol (2014) 1.13
Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol (2012) 1.10
Combinatorial peptide libraries: mining for cell-binding peptides. Chem Rev (2013) 1.07
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis (2011) 1.06
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol (2011) 0.99
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn (2013) 0.98
An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males. Br J Clin Pharmacol (2010) 0.97
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem (2012) 0.96
Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J (2012) 0.96
Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs (2012) 0.93
Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol (2013) 0.92
Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J (2012) 0.92
Treatment of immobilization-related hypercalcaemia with denosumab. Clin Kidney J (2012) 0.92
The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J (2011) 0.91
In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers. EJNMMI Res (2011) 0.90
Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics. CPT Pharmacometrics Syst Pharmacol (2012) 0.89
Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Front Pharmacol (2014) 0.87
The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. AAPS J (2012) 0.86
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther (2015) 0.86
Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics (2012) 0.85
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel (2012) 0.85
Targeted treatments of bone metastases in patients with lung cancer. Front Oncol (2014) 0.85
Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J (2010) 0.84
First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin. J Cardiovasc Pharmacol (2015) 0.83
The development of antibody-based immunotherapy for methamphetamine abuse: immunization, and virus-mediated gene transfer approaches. Curr Gene Ther (2013) 0.83
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research. Br J Clin Pharmacol (2015) 0.82
Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAPS J (2014) 0.82
Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus. Clin Pharmacokinet (2013) 0.82
Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. Haematologica (2013) 0.80
Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability. J Pharm Sci (2012) 0.80
Targeting FcRn for the modulation of antibody dynamics. Mol Immunol (2015) 0.80
Engineering upper hinge improves stability and effector function of a human IgG1. J Biol Chem (2011) 0.80
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol (2012) 0.79
PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice. Int J Pharm (2014) 0.79
Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys. MAbs (2013) 0.79
Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. Onco Targets Ther (2009) 0.79
Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol (2014) 0.79
Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS One (2013) 0.78
Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticals. Pharm Res (2014) 0.78
Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs (2016) 0.78
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies. MAbs (2014) 0.78
Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection. AAPS J (2015) 0.77
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vasc Health Risk Manag (2016) 0.77
Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition. CPT Pharmacometrics Syst Pharmacol (2014) 0.77
Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex. J Biol Chem (2015) 0.77
Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment. J Clin Pharmacol (2016) 0.76
An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Chemother Pharmacol (2014) 0.76
Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. J Oncol (2011) 0.76
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther (2016) 0.76
Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. Oncoimmunology (2016) 0.76
Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES. J Biol Chem (2017) 0.75
An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats. AAPS J (2015) 0.75
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. Clin Pharmacokinet (2017) 0.75
Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics. MAbs (2016) 0.75
Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies. Eur J Clin Pharmacol (2016) 0.75
Treatment of methamphetamine abuse: an antibody-based immunotherapy approach. J Food Drug Anal (2013) 0.75
Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization. Biomed Res Int (2015) 0.75
Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. MAbs (2016) 0.75
Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects. Clin Pharmacol Drug Dev (2015) 0.75
Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice. AAPS J (2015) 0.75
Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy. Cancer Immunol Res (2015) 0.75
Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women. J Clin Toxicol (2014) 0.75
Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan. J Pharmacokinet Pharmacodyn (2013) 0.75
Impact of denosumab on bone mass in cancer patients. Clin Pharmacol (2013) 0.75
Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. Int J Pharm (2013) 0.75
Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn. MAbs (2017) 0.75
Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Sci Rep (2017) 0.75
Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res (2017) 0.75
Correlation of screening and confirmatory results in tiered immunogenicity testing by solution-phase bridging assays. J Pharm Biomed Anal (2012) 1.43
Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today (2007) 1.25
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys (2004) 1.25
Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother (2012) 1.02
Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev Technol (2007) 1.02
An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males. Br J Clin Pharmacol (2010) 0.97
Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci (2004) 0.95
Application of analytical detection concepts to immunogenicity testing. Anal Chem (2007) 0.92
Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus. Clin Pharmacokinet (2013) 0.82
An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype. J Pharm Biomed Anal (2013) 0.80
Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticals. Pharm Res (2014) 0.78
Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology (Oxford) (2013) 0.77